ZBIO - Company ID 0001953926
Zenas BioPharma, Inc. trades as ZBIO and has a market capitalization of $1.86 B, making it the #2205 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $10.00M, up 100.0% from the prior year and net income of -$377.74M. This page tracks Zenas BioPharma, Inc. through 166 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -74.2% to -3777.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| SCHEDULE 13D | - | 2026-05-05 |
| Insider trade | 4 | 2026-04-29 |
| SCHEDULE 13D/A | - | 2026-04-02 |
| Insider trade | 4 | 2026-04-02 |
| Insider trade | 4 | 2026-04-01 |
The INDIGO study met its primary and all key secondary endpoints with statistically significant results -
BLA submission based on positive results from Phase 3 INDIGO trial -
Safety and efficacy results from the Phase 3 INDIGO trial to be presented by Emanuel Della Torre, M.D., Ph.D., on Thursday June 4, 2026, at 2:45 PM GMT -
The RSUs will vest in four (4) equal installments over a four-year period, with vesting as to twenty-five percent (25%) of the RSUs subject to the award on each of May 15, 2027, May 15, 2028, May 15, 2029 and May 15, 2030. Inducement Grants are subject to the employees’ continued service with Zenas through the applicable vesting dates. The Inducement Grants were granted pursuant to, and are subject to, the terms and conditions of the Company’s 2026 Inducement Plan and the applicable award agreement.
– Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results –
The largest companies sharing Zenas BioPharma, Inc.'s SEC industry classification (pharmaceutical preparations).
Zenas BioPharma, Inc. (ZBIO) has a market capitalization of $1.86 B as of 2026-07-09, ranking #2205 among US-listed companies.
Zenas BioPharma, Inc. reported revenue of $10.00M for fiscal year 2025, an increase of 100.0% year over year.
In its latest fiscal year Zenas BioPharma, Inc. reported a net loss of $377.74M.